SCHEMBL3336615

SCHEMBL3336615

CN[C@@H](Cc1c[nH]cn1)C(=O)OC(C)OC(=O)OC1CCCCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.34
▸ NPR3 P17342 1/20 0.32
▸ NLRP3 Q96P20 1/20 0.32
▸ EPHX1 P07099 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ MLNR O43193 1/20 0.31
▸ NR1I2 O75469 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ ESR1 P03372 1/20 0.31
▸ NR3C1 P04150 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ PGR P06401 1/20 0.31
▸ ADRB2 P07550 1/20 0.31
▸ CHRM2 P08172 1/20 0.31
▸ ADRB1 P08588 1/20 0.31
▸ HTR1A P08908 1/20 0.31
▸ ADRA2A P08913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3342710 0.99 CYP19A1 (0.33) CYP19A1NPR3NLRP3EPHX1SMN1; SMN2
SCHEMBL2474956 0.87 CYP19A1 (0.39) CYP19A1NPR3NLRP3EPHX1SMN1; SMN2
SCHEMBL28287713 0.78 NLRP3 (0.32) NPR3NLRP3
SCHEMBL12765185 0.74 HDAC6 (0.36) NLRP3MEN1KMT2AHSD17B10CYP2C19
SCHEMBL2059164 0.74 HDAC6 (0.36) NLRP3MEN1KMT2AHSD17B10CYP2C19
SCHEMBL28774335 0.74 — —
Hydrochloric Acid SCHEMBL9876601 0.73 HDAC6 (0.35) NLRP3HSD17B10CYP2C19
Hydrochloric Acid SCHEMBL3339175 0.73 HDAC6 (0.35) NLRP3HSD17B10CYP2C19
SCHEMBL7780238 0.72 CYP19A1 (0.39) CYP19A1NLRP3EPHX1SMN1; SMN2HPGD
SCHEMBL7780240 0.72 CYP19A1 (0.39) CYP19A1NLRP3EPHX1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202227-B1 NOVEL HISTIDINE DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO (JP) 2013-11-20 — — EP disclosed
US-8324261-B2 Histidine derivatives NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2012-12-04 — — US disclosed
EP-2202227-A1 NOVEL HISTIDINE DERIVATIVE Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2010-06-30 — — EP disclosed
US-20100152459-A1 NOVEL HISTIDINE DERIVATIVES NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2010-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152459-A1 NOVEL HISTIDINE DERIVATIVES HRH4, HNMT, HRH3 CYP19A1 4682/4885NPR3 782/4885NLRP3 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback